ylliX - Online Advertising Network
Press Release

Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Dupixent ® (dupilumab) SmPC update d with long-term data reinforc ing well -established safety profile in adults with moderate-to-severe atopic dermatitis

...read full article on GlobeNewsWire

ylliX - Online Advertising Network